Scott E Delacroix Jr M.D.
2.4K posts

Scott E Delacroix Jr M.D.
@UroCancer
Medical Director Urologic Oncology/GU Cancers. Mary Bird Perkins Cancer Center. Metairie, Louisiana. Bladder and Prostate Cancer subspecialty.




















It’s disappointing to me that TURBT continues to be dismissed as a “low-priority” procedure in so many training programs. This single step defines the entire course for a bladder cancer patient. Accurate diagnosis, precise staging, and the choice of therapy all hinge on a high quality TURBT. And the “advanced genomic analysis and molecular profiling” these same programs love to promote? It all begins with adequate, high-quality tissue obtained through a TURBT. Yet incomplete resections leave behind residual tumor in up to 78% of cases at restaging, leading to higher recurrence rates and unnecessary progression. If we are serious about improving outcomes in NMIBC - and even MIBC - we must treat TURBT with the respect it deserves: structured, deliberate training curricula, hands-on attending involvement, and real performance metrics. This is why the @IBCG_BladderCA will make this one of the focus topics of our retreat this year, #IBCG26 @UrogerliMD @JoshMeeks @bbmdmsk @siadaneshmand @RobertoContieri @paolo_gontero @ParamMariappan @joanfundi @jteoh_hk @spsutkaMD @WorldBladderCan @BladderCancerUS @drgaganprakash @SUO_YUO @veerukasi





The one point that the general public must understand is that the cost of medicine, the rise of hospitals systems, and the fall of private practice has occurred largely because government has allowed hospital systems to be paid a “facility fee” that independent physicians cannot collect. pgpf.org/article/what-i…






Great to reconnect with so many motivated clinical trialists, colleagues, and the #GU family at the @NRGOnc Winter Meeting #NRG2026! 2025 was a big year for NRG GU with landmark trials presented at ASTRO in plenary and clinical trials sessions (GU005, RTOG 0924, GU006) and two major bladder trials that were launched: 🔹 NRG GU014 PARRC 💉 — RT+IO vs chemoRT in NMIBC 🔹 NRG GU015 ARCHER 🏹 — 20 vs 5 (adaptive) fractions chemoRT in MIBC Lots more to come in 2026! Grateful to the PIs and study teams—and especially to the patients and families who make NRG trials possible. @snseyedinMD @jmmrad @DrHowardSandler @NehaVapiwala @DrPaulNguyen @RonaldChenMD @MaryFengMD @ChadTangMD @KHoffmanMD @BrianBaumannMD @CaPsurvivorship @EdwinPosadasMD @MiyamotoDavid @abhiAsolanki @bridget_koontz @MoningiShalini @HimanshuNagarMD @UroCancer @DrSpratticus @Katie_Spina @TylerSbrt @sophia_kamran @tranpt21 @aleberlin2 @a_dalpra @ndesai2005 @SeanSachdevMD @MassGenBrigham @NRGonc #NRGOncology #RadiationOncology #GUCancer #CancerResearch #OncologyCommunity #BladderCancer #ClinicalTrials #TeamScience








